5.0
30 Sept 2020
Anonymous employee
Current employee, more than 3 years
Recommend
CEO approval
Business outlook
Pros
Well entrenched in the biotech ecosystem
Cons
Broad mandate, therapeutics focused, less focus on growth equity and later stage
Top tier venture capital fund - Anonymous employee SR One Employee Review
30 Sept 2020
Anonymous employee